COYA News & Events

Coya Therapeutics (COYA) announced that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2.522M shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy's (RDY), $10M, and Greenlight Capital, an existing institutional stockholder of the company. The gross proceeds to the Company from the private placement are expected to be approximately $11.1M, before deducting offering expenses payable by the company. No broker, placement agent or investment banker was engaged in the transaction. The company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.

Coya Therapeutics announced that the FDA has accepted the company's investigational new drug application for COYA 302 for the treatment of frontotemporal dementia.

Coya Therapeutics announced that Health Canada has accepted, without objection, the clinical trial application for COYA 302 for the treatment of amyotrophic lateral sclerosis. The CTA acceptance by Health Canada allows for activation of clinical sites in Canada, enhancing patient recruitment alongside the U.S. clinical sites.

Coya Therapeutics announced that dosing of ALS patients in the company's ALSTARS trial of COYA 302 has commenced.